 | • レポートコード：MRC2303B090 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| モルドールインテリジェンス社の市場調査書では、世界の禁煙補助薬市場規模が予測期間中に年平均12.5％上昇すると推測されています。本調査書では、禁煙補助薬の世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（ニコチン置換療法、医薬品、電子タバコ、その他）分析、エンドユーザー別（病院内薬局、オンラインチャネル、小売薬局、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、NJOY、Pfizer Inc.、GlaxoSmithKline PLC、F. Hoffmann-La Roche AG、Novartis AG、Johnson and Johnson、Bayer AG、Cipla Ltd、Takeda Pharmaceuticals Co. Ltd、British American Tobacco PLC、Kimree Technology、Imperial Tobaccoなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の禁煙補助薬市場規模：製品別 - ニコチン置換療法の市場規模 - 医薬品の市場規模 - 電子タバコの市場規模 - その他禁煙補助薬の市場規模 ・世界の禁煙補助薬市場規模：エンドユーザー別 - 病院内薬局における市場規模 - オンラインチャネルにおける市場規模 - 小売薬局における市場規模 - その他エンドユーザーにおける市場規模 ・世界の禁煙補助薬市場規模：地域別 - 北米の禁煙補助薬市場規模 アメリカの禁煙補助薬市場規模 カナダの禁煙補助薬市場規模 メキシコの禁煙補助薬市場規模 … - ヨーロッパの禁煙補助薬市場規模 ドイツの禁煙補助薬市場規模 イギリスの禁煙補助薬市場規模 フランスの禁煙補助薬市場規模 … - アジア太平洋の禁煙補助薬市場規模 中国の禁煙補助薬市場規模 日本の禁煙補助薬市場規模 インドの禁煙補助薬市場規模 … - 南米/中東の禁煙補助薬市場規模 南アフリカの禁煙補助薬市場規模 ブラジルの禁煙補助薬市場規模 アルゼンチンの禁煙補助薬市場規模 … ・競争状況 ・市場機会・将来動向 |
The smoking cessation aids market is expected to witness a CAGR of 12.5% during the forecast period.
The impact of the COVID-19 pandemic is being felt across several markets. According to a study titled, “Association between Youth Smoking, Electronic Cigarette Use, and COVID-19,” published in October 2020, the COVID-19 diagnosis was five times more likely among users of e-cigarettes only but is also associated with the dual risk of e-cigarettes and cigarettes, hence, suggesting that e-cigarettes can be underlying risk factors for COVID-19. According to an article published in the official journal of ENSP, the European Network for Smoking and Tobacco Prevention, in September 2020, by Himanshu S. Gupte, tobacco use raises the risk of infection, increases the likelihood of complications, and increases the likelihood of the disease spreading. Only 30% of users said the current situation had influenced their tobacco use, with the most common effects being a lack of tobacco products and higher prices. During the lockdown, 34% of tobacco users quit tobacco in the population studied. Of this, 51% quit because of the lockdown and their concerns over COVID-19. Thus, the COVID-19 pandemic significantly impacted the smoking cessation aids market.
Smoking is one of the major causes of lung cancer and other respiratory and cardiac diseases. Awareness about these health hazards has influenced individuals to adopt smoking cessation therapies. The awareness gained by individuals through digital media, print media, and other sources of information has proved to be effective in curbing the nicotine addiction crisis to some extent.
Cigarette smoking remains the leading cause of preventable disease, disability, and death. According to the Centers for Disease Control and Prevention (CDC), in 2019, nearly 14 of every 100 US adults aged 18 years or older (14%) smoked cigarettes. This suggests a huge opportunity for de-addiction products. Also, this depicts growing awareness among people and their readiness to quit smoking. There are also non-government and government establishments working to educate and help people quit smoking and decrease the number of smokers. For example, “Tips from Former Smokers” is a campaign run by the Center for Disease and Control Prevention. Between 2012 and 2018, approximately 1 million people quit smoking as a result of Tips. Another 16 million people attempted to quit as a result of the campaign, and 129,000 people prevented premature death as a result of it.
Increasing product launch approvals by regulatory authorities are expected to boost the market over the forecast period. For instance, in July 2020, Dr Reddy’s Laboratories launched OTC Nicotine Polacrilex Lozenges in the US. The nicotine lozenge brands and store brand markets witnessed retail sales of about USD 200 million in 2020 in the US. The product is a significant addition to the company’s offering of Nicotine Replacement Therapies. Similarly, in April 2020, Philip Morris Products SA’s product IQOS Tobacco Heating System was authorized by the US Food and Drug Administration (USFDA) for marketing and distribution. These factors are considered to be the major factors contributing to the market’s growth.
Smoking Cessation Aids Market Trends
E-cigarettes Technology Expected to Show Steady Growth over the Forecast Period
E-cigarettes are battery-operated electronic cigarettes that are less toxic than traditional cigarettes. Electronic cigarettes, also known as e-cigs, e-vaping devices, vape pens, and electronic cigarettes, are made up of three main parts: a heating coil, a battery, and an e-liquid cartridge.
E-cigarettes are considered a healthy alternative to tobacco cigarettes and are estimated to be the fastest-growing segment over the forecast period. E-cigarettes are an effective alternative for reducing health conditions associated with tobacco, while nicotine replacement therapies work best for smoking cessation. E-cigarettes are a potential threat to tobacco-based cigarettes.
At the same time, they present an opportunity for tobacco manufacturers to enter a new emerging segment catering to the smoking population. Consumption of e-cigarettes is less harmful compared to regular cigarettes. The lack of smoke and no risk of passive smoking, permission to use even in no-smoking places, varying nicotine levels, and availability in various flavors are major driving factors for the e-cigarettes market. In addition, the increasing popularity of e-cigarettes backed by their electronic features is considered to be the major factor contributing to their increasing demand.
Additionally, regulatory authorities have approved e-cigarettes marketing. For instance, in October 2021, the US Food and Drug Administration issued marketing granted orders to RJ Reynolds (RJR) Vapor Company for its Vuse Solo closed electronic nicotine delivery system (ENDS) device and accompanying tobacco-flavored e-liquid pods, specifically, Vuse Solo Power Unit, Vuse Replacement Cartridge Original 4.8% G1, and Vuse Replacement Cartridge Original 4.8% G2. Thus, all these aforementioned factors are expected to boost the segment over the forecast period.
Asia-Pacific Expected to Show Fastest Growth over the Forecast Period
Asia-Pacific is expected to be the fastest-growing region for the market due to increasing awareness about smoking cessation and nicotine de-addiction products and a huge population. In a study titled “Tobacco Smoking and Mortality in Asia,” published by JAMA Network in March 2019, an international collaboration of researchers, led by those from Vanderbilt University, US, studied the trends in tobacco use in China, Japan, South Korea, Singapore, Taiwan, and India. It was estimated that 8.3 million deaths will be attributed to smoking by 2030, half of the world’s male smokers live in China, India, and Indonesia, and Asia is the world’s largest tobacco consumer and producer.
In January 2021, the World Health Organization launched an anti-tobacco campaign, which aims to create a favorable environment by promoting strong smoking cessation policies, raising awareness of the tobacco industry’s various tactics (such as organizing campaigns and engaging lobbyists to influence policy), and encouraging tobacco users to quit. Thus, rising awareness among individuals about smoking cessation is expected to drive the smoking cessation aids market over the forecast period.
North America is also found to be dominating the smoking cessation market due to its established healthcare infrastructure and rising disposable incomes.
Smoking Cessation Aids Market Competitor Analysis
The players in the smoking cessation aids market utilize various growth strategies, such as collaborations, partnerships, agreements, mergers, and acquisitions, to enhance their presence. The introduction of new products and collaborations with governments and NGOs to create awareness of smoking cessation also boost the market growth.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Large Population Addicted to Smoking
4.2.2 Awareness of the Hazards of Smoking
4.2.3 Banning Advertisements of Tobacco Products
4.3 Market Restraints
4.3.1 Adverse Effects of Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Product
5.1.1 Nicotine Replacement Therapy
5.1.1.1 NRT Gum
5.1.1.2 NRT Lozenges
5.1.1.3 NRT Inhalers
5.1.1.4 NRT Patches
5.1.1.5 Sprays
5.1.2 Drugs
5.1.3 Electronic Cigarettes
5.1.4 Other Products
5.2 End User
5.2.1 Hospital Pharmacies
5.2.2 Online Channels
5.2.3 Retail Pharmacies
5.2.4 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 NJOY
6.1.2 Pfizer Inc.
6.1.3 GlaxoSmithKline PLC
6.1.4 F. Hoffmann-La Roche AG
6.1.5 Novartis AG
6.1.6 Johnson and Johnson
6.1.7 Bayer AG
6.1.8 Cipla Ltd
6.1.9 Takeda Pharmaceuticals Co. Ltd
6.1.10 British American Tobacco PLC
6.1.11 Kimree Technology
6.1.12 Imperial Tobacco
7 MARKET OPPORTUNITIES AND FUTURE TRENDS